<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34789332</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>46</StartPage><MedlinePgn>46</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">46</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-021-00272-z</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by selective, early degeneration of motor neurons in the brain and spinal cord. Motor neurons have long axonal projections, which rely on the integrity of neuronal cytoskeleton and mitochondria to regulate energy requirements for maintaining axonal stability, anterograde and retrograde transport, and signaling between neurons. The formation of protein aggregates which contain cytoskeletal proteins, and mitochondrial dysfunction&#xa0;both have devastating effects on the function of neurons and are shared pathological features across several neurodegenerative conditions, including ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease and Charcot-Marie-Tooth disease. Furthermore, it is becoming increasingly clear that cytoskeletal integrity and mitochondrial function are intricately linked. Therefore, dysregulations of the cytoskeletal network and mitochondrial homeostasis and localization, may be common pathways in the initial steps of neurodegeneration. Here we review and discuss known contributors, including variants in genetic loci and aberrant protein activities, which modify cytoskeletal integrity, axonal transport and mitochondrial localization in ALS and have overlapping features with other neurodegenerative diseases. Additionally, we explore some emerging pathways that may contribute to this disruption in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theunissen</LastName><ForeName>Frances</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7092-8344</Identifier><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia. frances.theunissen@perron.uwa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia. frances.theunissen@perron.uwa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Phillip K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovi&#x107;</LastName><ForeName>Bojan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, the University of Sydney, Camperdown, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooshmand</LastName><ForeName>Kosar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, the University of Sydney, Camperdown, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkari</LastName><ForeName>P Anthony</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Duke University Medical Centre, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keon</LastName><ForeName>Matt</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia. mattk@genieus.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guennewig</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>GenieUs Genomics Pty Ltd, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre and Central Clinical School, Faculty of Medicine and Health, the University of Sydney, Camperdown, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Axonal transport</Keyword><Keyword MajorTopicYN="N">Cytoskeleton</Keyword><Keyword MajorTopicYN="N">Gut microbiome</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neurofilament</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing interests. BG is a director of Pacific Analytics PTY LTD &amp; SMRTR PTY LTD, Australia; a founding member of the International Cerebral Palsy Genetics Consortium and a member of the Australian Genomics Health Alliance.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34789332</ArticleId><ArticleId IdType="pmc">PMC8597313</ArticleId><ArticleId IdType="doi">10.1186/s40035-021-00272-z</ArticleId><ArticleId IdType="pii">10.1186/s40035-021-00272-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kapitein LC, Hoogenraad CC. Building the neuronal microtubule cytoskeleton. Neuron. 2015;87(3):492&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">26247859</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. J Cell Sci. 2012;125(9):2095&#x2013;2104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656622</ArticleId><ArticleId IdType="pubmed">22619228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Lasso DC, Rom&#xe1;-Mateo C, Pallard&#xf3; FV, Gonzalez-Cabo P. Much more than a scaffold: cytoskeletal proteins in neurological disorders. Cells. 2020;9(2):358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072452</ArticleId><ArticleId IdType="pubmed">32033020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal A, Drerup CM. Axonal transport and mitochondrial function in neurons. Front Cell Neurosci. 2019;13:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696875</ArticleId><ArticleId IdType="pubmed">31447650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju V, Lewis TL, Hirabayashi Y, Bergami M, Motori E, Cartoni R, et al. Pleiotropic mitochondria: the influence of mitochondria on neuronal development and disease. J Neurosci. 2019;39(42):8200&#x2013;8208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794931</ArticleId><ArticleId IdType="pubmed">31619488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106(44):18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, et al. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathol. 2009;29(6):672&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">19496940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells C, Brennan SE, Keon M, Saksena NK. Prionoid proteins in the pathogenesis of neurodegenerative diseases. Front Mol Neurosci. 2019;12:271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861308</ArticleId><ArticleId IdType="pubmed">31780895</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Dittlau KS, Van Den Bosch L. Axonal transport defects and neurodegeneration: molecular mechanisms and therapeutic implications. Semin Cell Dev Biol. 2020;99:133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">31542222</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A. Axonal transport of membranous and nonmembranous cargoes: a unified perspective. J Cell Biol. 2003;160(6):817&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173776</ArticleId><ArticleId IdType="pubmed">12642609</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, Das U, Tang Y, Roy S. Mechanistic logic underlying the axonal transport of cytosolic proteins. Neuron. 2011;70(3):441&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096075</ArticleId><ArticleId IdType="pubmed">21555071</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur EL. Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron. 2014;84(2):292&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4269290</ArticleId><ArticleId IdType="pubmed">25374356</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillaud L, El-Agamy SE, Otsuki M, Terenzio M. Anterograde axonal transport in neuronal homeostasis and disease. Front Mol Neurosci. 2020;13:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7531239</ArticleId><ArticleId IdType="pubmed">33071754</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Julien J-P. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci. 2013;14(3):161&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Grafstein B. Axonal transport: the intracellular traffic of the neuron. Compr Physiol. 2011 doi: 10.1002/cphy.cp010119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.cp010119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9(4):a018309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378049</ArticleId><ArticleId IdType="pubmed">28373358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ching GY, Liem RK. Analysis of the roles of the head domains of type IV rat neuronal intermediate filament proteins in filament assembly using domain-swapped chimeric proteins. J Cell Sci. 1999;112(Pt 13):2233&#x2013;2240.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362553</ArticleId></ArticleIdList></Reference><Reference><Citation>Straube-West K, Loomis PA, Opal P, Goldman RD. Alterations in neural intermediate filament organization: functional implications and the induction of pathological changes related to motor neuron disease. J Cell Sci. 1996;109(9):2319&#x2013;2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8886982</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D, Smith KE, O'Brien BJ, Angelides KJ. Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments. J Biol Chem. 1985;260(19):10736&#x2013;10747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner OI, Lifshitz J, Janmey PA, Linden M, McIntosh TK, Leterrier J-F. Mechanisms of mitochondria-neurofilament interactions. J Neurosci. 2003;23(27):9046&#x2013;9058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740819</ArticleId><ArticleId IdType="pubmed">14534238</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 1997;13(1):83&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9442869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15(12):691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558780</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Morfini GA. Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis. 2017;105:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522763</ArticleId><ArticleId IdType="pubmed">28411118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Niwa S, Tanaka Y. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron. 2010;68(4):610&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">21092854</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior R, Van Helleputte L, Benoy V, Van Den Bosch L. Defective axonal transport: a common pathological mechanism in inherited and acquired peripheral neuropathies. Neurobiol Dis. 2017;105:300&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">28238949</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JE, Goldstein LS. The genetics of axonal transport and axonal transport disorders. PLoS Genet. 2006;2(9):e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1584265</ArticleId><ArticleId IdType="pubmed">17009871</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry. 2009;48(9):2045&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693257</ArticleId><ArticleId IdType="pubmed">19152501</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495060</ArticleId><ArticleId IdType="pubmed">28062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. JNNP. 2016;87(11):1234&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099318</ArticleId><ArticleId IdType="pubmed">27172939</ArticleId></ArticleIdList></Reference><Reference><Citation>Blamire AM. MR approaches in neurodegenerative disorders. Prog Nucl Magn Reson Spectrosc. 2018;108:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30538047</ArticleId></ArticleIdList></Reference><Reference><Citation>Koikkalainen J, Rhodius-Meester H, Tolonen A, Barkhof F, Tijms B, Lemstra AW, et al. Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage Clin. 2016;11:435&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4827727</ArticleId><ArticleId IdType="pubmed">27104138</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh T, Jiao Y, Ferrando LM, Yablonska S, Li F, Horoszko EC, et al. Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci Rep. 2021;11(1):18916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8460779</ArticleId><ArticleId IdType="pubmed">34556702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali&#xf3; ML, Henriques E, Siena A, Bertoncini CRA, Gil-Mohapel J, Rosenstock TR. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front Neurosci. 2020 doi: 10.3389/fnins.2020.00679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00679</ArticleId><ArticleId IdType="pmc">PMC7373761</ArticleId><ArticleId IdType="pubmed">32760239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci. 2011;31(21):7817&#x2013;7830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, McLean J, Robertson J. Neuronal intermediate filaments and ALS: a new look at an old question. BBA Mol Basis Dis. 2006;1762(11&#x2013;12):1001&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">17045786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Bonetto V, Sorar&#xf9; G, Martinelli I, Parchi P, Liguori R, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegener. 2020;15(1):1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Miller CCJ. Neurofilaments and neurological disease. BioEssays. 2003;25(4):346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">12655642</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson R, Leung J, Bender J, Kirkcaldie M, Vickers J, King A. TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy. Dis Model Mech. 2021;14(2):dmm047548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888715</ArticleId><ArticleId IdType="pubmed">33408125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ML, Singleton AB, Hernandez D, Ward CM, Evey C, Sapp PA, et al. Mutations in neurofilament genes are not a significant primary cause of non-SOD1-mediated amyotrophic lateral sclerosis. Neurobiol Dis. 2006;21(1):102&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">16084104</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe A, Numakura C, Saito K, Koide H, Oka N, Honma A, et al. Neurofilament light chain polypeptide gene mutations in Charcot-Marie-Tooth disease: nonsense mutation probably causes a recessive phenotype. J Hum Genet. 2009;54(2):94&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">19158810</ArticleId></ArticleIdList></Reference><Reference><Citation>Horga A, Laur&#xe0; M, Jaunmuktane Z, Jerath NU, Gonzalez MA, Polke JM, et al. Genetic and clinical characteristics of NEFL-related Charcot-Marie-Tooth disease. JNNP. 2017;88(7):575&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580821</ArticleId><ArticleId IdType="pubmed">28501821</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlees J, Ackerley S, Grierson AJ, Jacobsen NJO, Shea K, Anderton BH, et al. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet. 2002;11(23):2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki T, Gotow T, Shiozaki M, Sakaue F, Saito T, Julien J-P, et al. Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. Hum Mol Genet. 2006;15(6):943&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci Lett. 2002;322(1):57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Q, Wang J. Detection of level and mutation of neurofilament mRNA in Alzheimer's disease. Zhonghua Yi Xue Za Zhi. 2002;82(8):519&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">12133495</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Rouleau GA, Krizus A, Julien JP. Polymorphism in the multi-phosphorylation domain of the human neurofilament heavy-subunit-encoding gene. Gene. 1993;132(2):297&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">8224877</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, Russ C, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Human Mol Genet. 1999;8(2):157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931323</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Krizus A, Martinoli MG, Meininger V, Dib M, Rouleau GA, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994;3(10):1757&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomkins J, Usher P, Slade JY, Ince PG, Curtis A, Bushby K, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS) NeuroReport. 1998;9(17):3967&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875737</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L, Carlomagno Y, Falasco L, Mellone S, Godi M, Cova E, et al. A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patient. Neurobiol Aging. 2011;32(3):552.e1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20363051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Larivi&#xe8;re R, Gowing G, Laurent S, Camu W, Bouchard JP, et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem. 2004;279(44):45951&#x2013;45956.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS) J Neuropathol Exp. 2000;59(11):972&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089575</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D, Hawley ZC, Strong MJ. Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Mol Brain. 2018;11(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054723</ArticleId><ArticleId IdType="pubmed">30029677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley ZC, Campos-Melo D, Strong MJ. MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS) Brain Res. 2019;1706:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">30385300</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D, Droppelmann CA, He Z, Volkening K, Strong MJ. Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. Mol Brain. 2013;6(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668997</ArticleId><ArticleId IdType="pubmed">23705811</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YM, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, Terao S, et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol. 2005;57(2):236&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668976</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp S, Kenna KP, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84(2):324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Keays DA, Tian G, Poirier K, Huang G-J, Siebold C, Cleak J, et al. Mutations in &#x3b1;-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans. Cell. 2007;128(1):45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885944</ArticleId><ArticleId IdType="pubmed">17218254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar RA, Pilz DT, Babatz TD, Cushion TD, Harvey K, Topf M, et al. TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Hum Mol Genet. 2010;19(14):2817&#x2013;2827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893812</ArticleId><ArticleId IdType="pubmed">20466733</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaglin XH, Poirier K, Saillour Y, Buhler E, Tian G, Bahi-Buisson N, et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet. 2009;41(6):746&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883584</ArticleId><ArticleId IdType="pubmed">19465910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell. 2010;140(1):74&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164117</ArticleId><ArticleId IdType="pubmed">20074521</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier K, Saillour Y, Bahi-Buisson N, Jaglin XH, Fallet-Bianco C, Nabbout R, et al. Mutations in the neuronal &#xdf;-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum Mol Genet. 2010;19(22):4462&#x2013;4473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298850</ArticleId><ArticleId IdType="pubmed">20829227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersheson J, Mencacci NE, Davis M, MacDonald N, Trabzuni D, Ryten M, et al. Mutations in the autoregulatory domain of &#x3b2;-tubulin 4a cause hereditary dystonia. Ann Neurol. 2013;73(4):546&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698699</ArticleId><ArticleId IdType="pubmed">23424103</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuss M, Heng JI, Poirier K, Tian G, Jaglin XH, Qu Z, et al. Mutations in the &#x3b2;-tubulin gene TUBB5 cause microcephaly with structural brain abnormalities. Cell Rep. 2012;2(6):1554&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595605</ArticleId><ArticleId IdType="pubmed">23246003</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier K, Lebrun N, Broix L, Tian G, Saillour Y, Boscheron C, et al. Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat Genet. 2013;45(6):639&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826256</ArticleId><ArticleId IdType="pubmed">23603762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert SP, Webb MR, Brune M, Johnson KA. Pathway of processive ATP hydrolysis by kinesin. Nature. 1995;373(6516):671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855160</ArticleId><ArticleId IdType="pubmed">7854446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennerich A, Vale RD. Walking the walk: how kinesin and dynein coordinate their steps. Curr Opin Cell Biol. 2009;21(1):59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668149</ArticleId><ArticleId IdType="pubmed">19179063</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell PD, Shen K, Sapio MR, Glenn TD, Talbot WS, Marlow FL. Unique function of Kinesin Kif5A in localization of mitochondria in axons. J Neurosci. 2014;34(44):14717&#x2013;14732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212069</ArticleId><ArticleId IdType="pubmed">25355224</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, M&#xfc;ller K, Grehl T, Petri S, Meyer T, et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141(3):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S, Dalgard CL, Ding J, Chi&#xf2; A, Alba C, Hupalo DN, et al. Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology. 2020;95(22):1015&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734922</ArticleId><ArticleId IdType="pubmed">33077544</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone M, Trabacca A, Panzeri E, Losito L, Citterio A, Bassi MT. KIF5A and ALS2 variants in a family with hereditary spastic paraplegia and amyotrophic lateral sclerosis. Front Neurol. 2018;9:1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293196</ArticleId><ArticleId IdType="pubmed">30581417</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M, Piccinelli SC, Palmieri I, Necchini N, Valente M, Zanella I, et al. A novel mutation in the stalk domain of KIF5A causes a slowly progressive atypical motor syndrome. J Clin Med. 2019;8(1):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6352268</ArticleId><ArticleId IdType="pubmed">30583522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97(6):1268&#x2013;83.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Wang Y, Xu H, Fu Y, Qian T, Bo D, et al. DYNC1H1 Mutation causes proprioceptive sensory neuron loss and impaired retrograde axonal transport of dorsal root ganglion neurons. CNS Neurosci Ther. 2016;22(7):593&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492895</ArticleId><ArticleId IdType="pubmed">27080913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X-J, Levedakou EN, Millen KJ, Wollmann RL, Soliven B, Popko B. Proprioceptive sensory neuropathy in mice with a mutation in the cytoplasmic Dynein heavy chain 1 gene. J Neurosci. 2007;27(52):14515&#x2013;14524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673431</ArticleId><ArticleId IdType="pubmed">18160659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsurusaki Y, Saitoh S, Tomizawa K, Sudo A, Asahina N, Shiraishi H, et al. A DYNC1H1 mutation causes a dominant spinal muscular atrophy with lower extremity predominance. Neurogenetics. 2012;13(4):327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">22847149</ArticleId></ArticleIdList></Reference><Reference><Citation>Weedon MN, Hastings R, Caswell R, Xie W, Paszkiewicz K, Antoniadi T, et al. Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet. 2011;89(2):308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155164</ArticleId><ArticleId IdType="pubmed">21820100</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilari&#xf1;o-G&#xfc;ell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, et al. Characterization of DCTN1 genetic variability in neurodegeneration. Neurology. 2009;72(23):2024&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692178</ArticleId><ArticleId IdType="pubmed">19506225</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33(4):455&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Daud D, Griffin H, Douroudis K, Kleinle S, Eglon G, Pyle A, et al. Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering. J Neurol. 2015;262(7):1673&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503877</ArticleId><ArticleId IdType="pubmed">25957632</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Phaneuf D, Cordeau P, Boutej H, Kriz J, Julien J-P. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD. Mol Neurodegener. 2021;16(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792109</ArticleId><ArticleId IdType="pubmed">33413517</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal-Bauernschubert L, L&#xfc;ningschr&#xf6;r P, Moradi M, Dombert B, Surrey V, et al. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol Commun. 2020;8(1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22(8):869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori I, Ferri A, Scaricamazza S, Giovannelli I, Serrano A, Rossi S, et al. Differential toxicity of TAR DNA-binding protein 43 isoforms depends on their submitochondrial localization in neuronal cells. J Neurochem. 2018;146(5):585&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">29779213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Deng J, Dong J, Liu J, Bigio EH, Mesulam M, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15(5):e1007947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183(3):636&#x2013;49.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer AL, Abdullah A, Taylor JM, Crack PJ. The complexity of the cGAS-STING pathway in CNS pathologies. Front Neurosci. 2021;15:621501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900568</ArticleId><ArticleId IdType="pubmed">33633536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliter DA, Martinez J, Hao L, Chen X, Sun N, Fischer TD, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561(7722):258&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362342</ArticleId><ArticleId IdType="pubmed">30135585</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrot R, Berges R, Bocquet A, Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol. 2008;38(1):27&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18649148</ArticleId></ArticleIdList></Reference><Reference><Citation>Villal&#xf3;n E, Barry DM, Byers N, Frizzi K, Jones MR, Landayan DS, et al. Internode length is reduced during myelination and remyelination by neurofilament medium phosphorylation in motor axons. Exp Neurol. 2018;306:158&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994378</ArticleId><ArticleId IdType="pubmed">29772247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 1996;19(1):187&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">8833441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai H, Toshimori M, Shibata H, Kitagawa M, Shimakawa M, Miyahara M, et al. PKN associates and phosphorylates the head-rod domain of neurofilament protein. J Biol Chem. 1996;271(16):9816&#x2013;9822.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621664</ArticleId></ArticleIdList></Reference><Reference><Citation>Manser C, Stevenson A, Banner S, Davies J, Tudor EL, Ono Y, et al. Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport. FEBS Lett. 2008;582(15):2303&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516414</ArticleId><ArticleId IdType="pubmed">18519042</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea TB, Chan WKH. Regulation of neurofilament dynamics by phosphorylation. Eur J Neurosci. 2008;27(8):1893&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pubmed">18412610</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Geisler S, DiAntonio A. Dynamic regulation of SCG10 in regenerating axons after injury. Exp Neurol. 2014;252:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947015</ArticleId><ArticleId IdType="pubmed">24246279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvin S, Sobel A. Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration. Prog Neurobiol. 2015;126:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25449700</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, et al. SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci USA. 2012;109(52):E3696&#x2013;E3705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535671</ArticleId><ArticleId IdType="pubmed">23188802</ArticleId></ArticleIdList></Reference><Reference><Citation>Tararuk T, Ostman N, Li W, Bj&#xf6;rkblom B, Padzik A, Zdrojewska J, et al. JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol. 2006;173(2):265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063817</ArticleId><ArticleId IdType="pubmed">16618812</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhang Y, Wang M, Song W-M, Shen Q, McKenzie A, et al. The landscape of multiscale transcriptomic networks and key regulators in Parkinson&#x2019;s disease. Nat Commun. 2019;10(1):5234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6868244</ArticleId><ArticleId IdType="pubmed">31748532</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Investig. 2020;130(11):6080&#x2013;6092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardanho-Ramos C, Faria-Pereira A, Morais VA. Orchestrating mitochondria in neurons: Cytoskeleton as the conductor. Cytoskeleton. 2020;77(3&#x2013;4):65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187307</ArticleId><ArticleId IdType="pubmed">31782907</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B, Li&#xe9;vens JC. Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway? Neural Regen Res. 2017;12(7):1052&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558479</ArticleId><ArticleId IdType="pubmed">28852382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N, Haney MS, Couthouis J, Morgens DW, Benjamin A, Wu K, et al. Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72. Brain Res. 2020;1728:146601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539795</ArticleId><ArticleId IdType="pubmed">31843624</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Yamano K, Head BP, Kawajiri S, Cheung JT, Wang C, et al. Mutations in FIS1 disrupt orderly disposal of defective mitochondria. Mol Biol Cell. 2014;25(1):145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873885</ArticleId><ArticleId IdType="pubmed">24196833</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitzig MT, Alleyn MD, Lockey RF, Kolliputi N. A mitochondrial delicacy: dynamin-related protein 1 and mitochondrial dynamics. Am J Physiol Cell Physiol. 2018;315(1):C80&#x2013;C90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087727</ArticleId><ArticleId IdType="pubmed">29669222</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Z, Huang Z, Xie F, Chen L. Dynamin-related protein 1: a critical protein in the pathogenesis of neural system dysfunctions and neurodegenerative diseases. J Cell Physiol. 2019;234(7):10032&#x2013;10046.</Citation><ArticleIdList><ArticleId IdType="pubmed">30515821</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, Lee JH, Chung AY, Jo Y, Shin Jh, Park HC, et al. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020;11(10):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578657</ArticleId><ArticleId IdType="pubmed">33087694</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkov A, Abdu U. Regulation of long-distance transport of mitochondria along microtubules. Cell Mol Life Scis. 2018;75(2):163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">28702760</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, M&#xf3;rotz GM, Stoica R, Tudor EL, Lau KF, Ackerley S, et al. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Hum Mol Genet. 2012;21(6):1299&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284118</ArticleId><ArticleId IdType="pubmed">22131369</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau K-F, et al. ER&#x2013;mitochondria associations are regulated by the VAPB&#x2013;PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun. 2014;5(1):3996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="pubmed">24893131</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R, Paillusson S, Gomez-Suaga P, Mitchell JC, Lau DH, Gray EH, et al. ALS/FTD-associated FUS activates GSK-3&#x3b2; to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. EMBO Rep. 2016;17(9):1326&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007559</ArticleId><ArticleId IdType="pubmed">27418313</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf3;rotz GM, De Vos KJ, Vagnoni A, Ackerley S, Shaw CE, Miller CC. Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum Mol Genet. 2012;21(9):1979&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315205</ArticleId><ArticleId IdType="pubmed">22258555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011;147(4):893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261796</ArticleId><ArticleId IdType="pubmed">22078885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Sawada T, Lee S, Yu W, Silverio G, Alapatt P, et al. Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet. 2012;8(3):e100537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291531</ArticleId><ArticleId IdType="pubmed">22396657</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn PMJ, Moreira PI, Ambr&#xf3;sio AF, Alves CH. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol Commun. 2020;8(1):189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654589</ArticleId><ArticleId IdType="pubmed">33168089</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Lim J, Wang Q, Purtell K, Wu S, Palomo GM, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16(5):917&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144840</ArticleId><ArticleId IdType="pubmed">31362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017;10(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiji M, Takahashi T, Fukuba H, Yamashita H, Kohriyama T, Matsumoto M. White matter lesions in the brain with frontotemporal lobar degeneration with motor neuron disease: TDP-43-immunopositive inclusions co-localize with p62, but not ubiquitin. Acta Neuropathol. 2008;116(2):183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">18584184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci. 2006;249(1):13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820172</ArticleId></ArticleIdList></Reference><Reference><Citation>Matenia D, Hempp C, Timm T, Eikhof A, Mandelkow E-M. Microtubule affinity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: effects on mitochondrial transport. J Biol Chem. 2012;287(11):8174&#x2013;8186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318756</ArticleId><ArticleId IdType="pubmed">22238344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills RD, Sim CH, Mok SS, Mulhern TD, Culvenor JG, Cheng H-C. Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1) J Neurochem. 2008;105(1):18&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221368</ArticleId></ArticleIdList></Reference><Reference><Citation>Knippenberg S, Sipos J, Thau-Habermann N, K&#xf6;rner S, Rath KJ, Dengler R, et al. Altered expression of DJ-1 and PINK1 in sporadic ALS and in the SOD1(G93A) ALS mouse model. J Neuropathol Exp Neurol. 2013;72(11):1052&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">24128678</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo GM, Granatiero V, Kawamata H, Konrad C, Kim M, Arreguin AJ, et al. Parkin is a disease modifier in the mutant SOD1 mouse model of ALS. EMBO Mol Med. 2018;10(10):e8888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6180298</ArticleId><ArticleId IdType="pubmed">30126943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Duan Y, Qin C, Li J-C, Duan G, Deng X, et al. Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy. Cell Death Dis. 2018;9(10):953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148241</ArticleId><ArticleId IdType="pubmed">30237395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Deng J, Wang P, Yang M, Chen X, Zhu L, et al. PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration. Hum Mol Genet. 2016;25(23):5059&#x2013;5068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078632</ArticleId><ArticleId IdType="pubmed">27794540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Hirabayashi Y, Kwon S-K, Lewis TL, Polleux F. Emerging roles of mitochondria in synaptic transmission and neurodegeneration. Curr Opin Physiol. 2018;3:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6178220</ArticleId><ArticleId IdType="pubmed">30320242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai H. The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J Biochem. 2003;133(1):17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozsarac N, Weible M, 2nd, Reynolds AJ, Hendry IA. Activation of protein kinase C inhibits retrograde transport of neurotrophins in mice. J Neurosci Res. 2003;72(2):203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671995</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Yamamoto H, Hanamura K, Mehruba M, Kawamata T, Morisaki H, et al. PKN1 promotes synapse maturation by inhibiting mGluR-dependent silencing through neuronal glutamate transporter activation. Commun Biol. 2020;3(1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691520</ArticleId><ArticleId IdType="pubmed">33244074</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275:162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Raval U, Harary JM, Zeng E, Pasinetti GM. The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders. Expert Rev Neurother. 2020;20(7):673&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387222</ArticleId><ArticleId IdType="pubmed">32459513</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar SR, Mazumder PM, Chatterjee K, Sarkar A, Adhikary M, Mukhopadhyay K, et al. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline. Physiol Behav. 2021;236:113411.</Citation><ArticleIdList><ArticleId IdType="pubmed">33811908</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddy SL, Giovannelli I, Sassani M, Cooper-Knock J, Snyder MP, Segal E, et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS) BMC Med. 2021;19(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816375</ArticleId><ArticleId IdType="pubmed">33468103</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccolai E, Di Pilato V, Nannini G, Baldi S, Russo E, Zucchi E, et al. The gut microbiota-immunity axis in ALS: a role in deciphering disease heterogeneity? Biomedicines. 2021;9(7):753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301418</ArticleId><ArticleId IdType="pubmed">34209688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertzberg VS, Singh H, Fournier CN, Moustafa A, Polak M, Kuelbs CA, et al. Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls. Amyotroph Lateral Scler Frontotemporal Degener. 2021 doi: 10.1080/21678421.2021.1904994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1904994</ArticleId><ArticleId IdType="pubmed">33818222</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker A, Fonseca S, Carding SR. Gut microbes and metabolites as modulators of blood&#x2013;brain barrier integrity and brain health. Gut Microbes. 2020;11(2):135&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053956</ArticleId><ArticleId IdType="pubmed">31368397</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):186&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">33135936</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A, Mach N. The crosstalk between the gut microbiota and mitochondria during exercise. Front Physiol. 2017;8:319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437217</ArticleId><ArticleId IdType="pubmed">28579962</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503625</ArticleId><ArticleId IdType="pubmed">32887215</ArticleId></ArticleIdList></Reference><Reference><Citation>Desale SE, Chinnathambi S. Role of dietary fatty acids in microglial polarization in Alzheimer&#x2019;s disease. J Neuroinflamm. 2020;17(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7093977</ArticleId><ArticleId IdType="pubmed">32209097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>